FDA Investigator Geoffrey K Kilili

Geoffrey K Kilili has conducted inspections on 80 sites in 8 countries as of 29 Apr 2024. See below for a list of the FDA enforcement documents resulting from those inspections.

Investigator Details

Number of Inspected Sites:
80
Last Inspection Date:
29 Apr 2024
Investigator Role:
FDA Investigator
Redica ID:
100003235
Countries of Inspections:
United States of America, India, Hungary, Georgia, Argentina, Brazil, Peru, Latvia
FDA Investigators that have inspected at least one site in common with Geoffrey K Kilili:
Alanna L Mussawwir Bias, Allen F Hall, Allison C Hunter, Althea A Williams, Amanda E Lewin, PhD, Andrew J Barrowcliff, Andria L Kuhlman, Anna M Brannen, Annemarie Kleiza, Annette Melendez, Arindam Dasgupta, PhD, Barbara A Rusin, Barbara M Frazier, Brandy D Brown, Brittany M Kershaw, Carol Rivera Lopez, PhD, Cassandra L Winters, Cheryl A Grandinetti, Ching Jeyg Chang, Christina L Bigham, Christopher T Middendorf, Corrine M Carter, Courtney N Long, Craig T Rybus, Cynthia F Kleppinger, MD, Cynthia L Rakestraw, Cynthia T Cain, D'arbra R Blankenship, Daniel L Aisen, David L Chon, Dawn C Olenjack, Dell S Moller, Demitria J Xiradakis, Dolores Harper, Dr. Abhijit Raha, PhD, Dr. Mark J Seaton, PhD, Dr. Sriram Subramaniam, PhD, Dr. Zhou Chen (nmi), MD PhD, Dylan D Yao, MD, PhD, Ebony D Sanon, Edward R Kay, Erin A Wall, Fatima Bassa, Felicia E Armbrustmacher, Felicia E Hinojosa, Gary J Hagan, Gene D Arcy, Gene R Gunn, Gilbert J Heidenblut, Gregson A Joseph, Gulshan R Anand, Hasan A Irier, PhD, Hugh M Mcclure, II, Hyojong Kwon, PhD, Jacqueline S Warner, James R Fleckenstein, Jane M Kreis, Janet L Bowen, Janete F Guardia, Javonica F Penn, Jazmine N Still, Jennifer C Adams, Jennifer L Jager, Jennifer L Sheehan, John A Kadavil, PhD, John Dan, Joseph L Despins, PhD, Joshua P Wireman, Jyoti B Patel, PhD, Ka L Wong, Kara A Scheibner, PhD, Karen M Cooper, Karen M Kondas, Kathleen D Culver, Kathryn Suttling, Keith J Mason, Jr, Kelli L Wilkinson, Kilili Kilili, Geoffrey K, Kimberley A Ricketts, Kimberly A Joseph, Kip J Hanks, Kirk A Dymbrowski, Kirtida Patel, L Gnnmassimia Massimilla, PharmD, Laine P Myers, Lakecha N Lewis, Laura E Garcia, Laureen M Geniusz, Lauren N Howard, Leslie R Clark, Li Hongpaul Yeh, PhD, Lianji Jin, Linda R Kuchenthal, Lindsey M Schwierjohann, Lisa R Hilliar, Lori A Gioia, Luann Mckinney, Marcia A Worley, Mark E Parmon, Mary E Storch, Matthew B Casale, Matthew C Watson, Matthew J Gretkierewicz, Michael E Campbell, Michael G Mayfield, Michael P Anthony, Michele L Glendenning, Mike M Rashti, Mishelle L Harriger, Nancy L Neiger, Nicholas L Paulin, Nutan Mytle, Paul E Stein, Paula J Bretz, Phillip M Pontikos, Pifer, Rebecca Rodriguez, Rebecca T Davis, Richard W Berning, Rosanna M Goodrich, Ruben C Ayala, PharmD, Sam Pepe, Scott B Laufenberg, Stephen J Kilker, Susan D Yuscius, Susanne M Richardson, MS RAC, Tamara M Kays, Teresa K Kastner, Thea C Grome, Thomas W Nojek, Thunder N Dunkijacobs, Timothy C Grome, Tracey L Harris, Travis V Hull, Ucheabuchi Cchudi Nwankwor, Victoria M Daddeo, Wayne D Mcgrath, Wr Bowman, Yiying E Chen, Yiyue Zhang (nmi), PhD, Young M Choi, PhD, Young M Yoon, Yvette Mlacour Davis

Geoffrey K Kilili's Documents

Publish Date Document Type Title
August, 2018 EIR Charles River Laboratories Ashland, LLC - EIR, 2018-08-03
April, 2017 EIR Battelle Memorial Institute - EIR, 2017-04-21
October, 2017 EIR Ronald F. Budzik Jr., MD - EIR, 2017-10-17
August, 2021 FDA 483 AmplifyBio, LLC. - Form 483, 2021-08-05
July, 2023 FDA 483 American Regent, Inc. - Form 483, 2023-07-20
July, 2017 FDA 483 Response Cleveland Medical Devices Inc - Form 483R, 2017-07-07
July, 2017 FDA 483 Cleveland Medical Devices Inc - Form 483, 2017-07-07
June, 2023 FDA 483 Vantage Specialty Ingredients, Inc. - Form 483, 2023-06-27
February, 2017 EIR Samir Arora, MD - EIR, 2017-02-17
February, 2018 FDA 483 Jaglowski, Samantha - Form 483, 2018-02-14
January, 2024 FDA 483 ISP Chemicals LLC - Form 483, 2024-01-29
April, 2024 FDA 483 GOJO Industries, Inc - Form 483, 2024-04-01
September, 2022 FDA 483 Martin T. Taylor, DO, PhD - Form 483, 2022-09-30
September, 2021 EIR Agios Pharmaceuticals, INC. - EIR, 2021-09-24
October, 2017 FDA 483 Response Ronald F. Budzik Jr., MD - Form 483R, 2017-11-27
December, 2018 EIR AtriCure, Inc. - EIR, 2018-12-13
March, 2019 EIR Nationwide Children's Hospital IRB - EIR, 2019-03-11
February, 2018 EIR Jaglowski, Samantha - EIR, 2018-02-14
January, 2017 FDA 483 Davis Remington Inc - Form 483, 2017-01-27
September, 2023 FDA 483 Safecor Health, LLC - Form 483, 2023-09-01
February, 2021 FDA 483 Sagar Sardesai, M.D. - Form 483, 2021-02-12
February, 2017 FDA 483 Samir Arora, MD - Form 483, 2017-02-17
November, 2019 EIR Battelle Memorial Institute - EIR, 2019-11-08
October, 2020 EIR Charles River Laboratories Inc - EIR, 2023-10-17
July, 2017 EIR Cleveland Medical Devices Inc - EIR, 2017-07-07
May, 2017 EIR Nationwide Children's Hospital IRB - EIR, 2017-05-26
December, 2017 FDA 483 Shivkamini Somasundaram, M.D. - Form 483, 2017-12-18
July, 2021 EIR Axsome Therapeutics, Inc. - EIR, 2021-07-15
January, 2017 EIR Davis Remington Inc - EIR, 2017-01-27
October, 2023 FDA 483 Novartis Manufacturing LLC - Form 483, 2023-10-27
August, 2021 FDA 483 Battelle Memorial Institute - Form 483, 2021-08-05
October, 2017 FDA 483 Ronald F. Budzik Jr., MD - Form 483, 2017-10-17
March, 2018 FDA 483 Sergio D. Bergese - Form 483, 2018-03-30
October, 2019 FDA 483 Mount Carmel Health System IRB - Form 483, 2019-10-29
January, 2021 FDA 483 Sameek Roychowdhury, MD - Form 483, 2021-01-22
November, 2023 FDA 483 Amgen Inc. - Form 483, 2023-11-30
June, 2018 FDA 483 Michael Racke MD - Form 483, 2018-06-15
September, 2019 FDA 483 Jennifer Woyach, M.D. - Form 483, 2019-09-03
January, 2018 FDA 483 David O'Malley, MD - Form 483, 2018-01-23
July, 2024 FDA 483 Avlon Industries Inc - Form 483, 2024-07-15
September, 2024 FDA 483 3M Company - Form 483, 2024-09-06
October, 2024 FDA 483 Induction Therapies, LLC - Form 483, 2024-10-18

Experience Redica Systems’ NEW investigator profiles and dashboards

Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:

  • Total inspections conducted
  • 483 rate
  • OAI rate
  • Warning Letter rate
  • Inspections by Industry, Scope, and Inspection Reason
  • And much more

Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.

FDA Investigator Profile Icon

Talk to sales to access our investigator profiles

Loading...

Investigator Profiles Are Just the Tip of the Iceberg

Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:

Inspection Intelligence

  • Pre-Approval Inspection (PAI) trends
  • The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
  • Latest 483s: see what the trends are across all FDA Investigators
  • CFR Heatmap: Citations aggregated by Subpart by Year

Vendor Intelligence

  • Full inspection histories for your vendors down to the specific site level
  • All of the functionality mentioned above but isolated to just your vendors

Regulatory Intelligence

  • Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
  • All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more